Healthcare professionals' perceptions and management of obesity & knowledge of glucagon, GLP‐1, GIP receptor agonists, and dual agonists
Abstract Background Anti‐obesity medications (AOMs) have historically had limited weight‐loss efficacy. However, newer glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA)–based therapies seem to be more effective, including dual agonists of GLP‐1R and the glucagon receptor (GCGR) or glucose‐dependen...
| Autors principals: | , , , |
|---|---|
| Format: | Article |
| Idioma: | English |
| Publicat: |
Wiley
2024-06-01
|
| Col·lecció: | Obesity Science & Practice |
| Matèries: | |
| Accés en línia: | https://doi.org/10.1002/osp4.756 |